March 10, 2023
For the nine months ended January 31 ,2023, Jamaica Broilers Group (JBG) reported total revenues of $68.51 billion, a 27% increase on the $54.02 billion reported in 2022. For the quarter, revenues closed at $22.67 billion (2022: $18.94 billion). Total revenue for the nine months is broken down as follows. Of total revenues:
- The Jamaica Operations contributed $43.82 billion (2022: $32.33 billion). The upward movement was due to “increased production and sale of poultry, as well as increased sale of baby chicks to our small farmers.”
- US Operations recorded revenue of $28.89 billion (2022: $25.00 billion), this increase according to management “was primarily driven by the increased production and sales in The Best Dressed Chicken line of products.”
Cost of Sales grew by 23% to $51.92 billion from $42.34 billion in 2022. As such, gross profit for the nine months reflected an increase of 42% to close at $16.59 billion versus $11.69 billion booked for the corresponding period in 2022.
Other income fell 55% from $846.58 million in 2022 to $384.09 million in 2023. Distribution costs increased by 17% to close at $2.17 billion relative to $1.86 billion recorded for the prior year’s comparable period, while administration and other expenses rose by 11% to $7.99 billion (2022: $7.22 billion).
Operating profit for the period increased by 97%, totaling $6.82 billion relative to $3.46 billion for the nine months ended January 2022. For the quarter, operating profit closed at $2.37 billion (2022: $1.74 billion).
JBG reported $10.13 million for finance income for the period (2022: $12.67 million).
Profit before taxation for the period rose to $5.55 billion (2022: $2.66 billion). Tax charges for the nine months totalled $1.04 billion (2022: $547.43 million).
As such, net profit amounted to $3.39 billion, a 66% increase compared to the $2.04 billion booked for the same period in 2022. While, for the quarter, net profit amounted to $1.48 billion (2022: $1.17 billion).
Net profit attributable to shareholders amounted to $3.56 billion relative to $2.05 billion booked for the comparable period in 2022. As for the quarter, net profit attributable to shareholders amounted to $1.48 billion (2022: $1.17 billion).
Total comprehensive income for the period amounted to $3.88 billion relative to $2.08 billion recorded in 2022.
Consequently, earnings per share for the nine months ended January 2023 amounted to $2.96 (2022: $1.71). The trailing earnings per share amounted to $3.87. The total shares used in our calculation amounted to 1,199,276,400 units. Notably, JBG last traded on March 9, 2023 at a price of $38.50 with a corresponding P/E ratio of 9.96 times.
Balance sheet at a glance:-
Total assets amounted to $70.46 billion as at January 31, 2023 relative to $55.46 billion a year prior. The increase in total assets was due mainly an increase in ‘Biological Assets’ and ‘Property, Plant and Equipment’ which rose 39% and 34% respectively. ‘Biological Assets’ and ‘Property, Plant and Equipment’ as at January 31 2023 amounted to $17.70 billion (2022: $12.75 billion) and $18.61 billion (2022: $13.94 billion) respectively.
Shareholders equity as at January 31, 2023 amounted to $24.53 billion (2022: $20.66 billion), with a book value per share of $20.46 (2022: $17.23).
Disclaimer:
Analyst Certification -The views expressed in this research report accurately reflect the personal views of Mayberry Investments Limited Research Department about those issuer (s) or securities as at the date of this report. Each research analyst (s) also certify that no part of their compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view (s) expressed by that research analyst in this research report.
Company Disclosure -The information contained herein has been obtained from sources believed to be reliable, however its accuracy and completeness cannot be guaranteed. You are hereby notified that any disclosure, copying, distribution or taking any action in reliance on the contents of this information is strictly prohibited and may be unlawful. Mayberry may effect transactions or have positions in securities mentioned herein. In addition, employees of Mayberry may have positions and effect transactions in the securities mentioned herein.
